Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
Eric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-12-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-of-tiotropiumndasholodaterol-fixed-dose-combination-in-copd-peer-reviewed-article-COPD |
| _version_ | 1819126471738785792 |
|---|---|
| author | Derom E Brusselle GG Joos GF |
| author_facet | Derom E Brusselle GG Joos GF |
| author_sort | Derom E |
| collection | DOAJ |
| description | Eric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium–olodaterol 5–5 µg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium–olodaterol 5–5 µg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance. Improvements exceeded the minimal clinically important difference (MCID) for forced expiratory volume in 1 second (FEV1), dyspnea, and quality of life. Differences between tiotropium–olodaterol 5–5 µg and the respective monocomponents were statistically significant for FEV1, dyspnea, markers of hyperinflation, use of rescue medication, and health-related quality of life, but did not reach the MCID. However, dual bronchodilatation significantly increased the number of patients who exceeded the MCID for dyspnea and quality of life. Moreover, tiotropium–olodaterol 5–5 µg was significantly more effective than salmeterol–fluticasone (FDC) twice daily at improving pulmonary function. Differences between tiotropium–olodaterol and other LAMA/LABA FDCs were not observed for FEV1 or other efficacy markers. Therefore, tiotropium–olodaterol is a valuable option in the treatment of COPD patients who remain symptomatic under monotherapy. Keywords: COPD, bronchodilatation, dyspnea, exacerbation, exercise tolerance, LABA, LAMA, spirometry |
| first_indexed | 2024-12-22T07:56:34Z |
| format | Article |
| id | doaj.art-4628e7dee6744f96988bf8d93c32f923 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-22T07:56:34Z |
| publishDate | 2016-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-4628e7dee6744f96988bf8d93c32f9232022-12-21T18:33:21ZengDove Medical PressInternational Journal of COPD1178-20052016-12-01Volume 113163317730457Efficacy of tiotropium–olodaterol fixed-dose combination in COPDDerom EBrusselle GGJoos GFEric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium–olodaterol 5–5 µg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium–olodaterol 5–5 µg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance. Improvements exceeded the minimal clinically important difference (MCID) for forced expiratory volume in 1 second (FEV1), dyspnea, and quality of life. Differences between tiotropium–olodaterol 5–5 µg and the respective monocomponents were statistically significant for FEV1, dyspnea, markers of hyperinflation, use of rescue medication, and health-related quality of life, but did not reach the MCID. However, dual bronchodilatation significantly increased the number of patients who exceeded the MCID for dyspnea and quality of life. Moreover, tiotropium–olodaterol 5–5 µg was significantly more effective than salmeterol–fluticasone (FDC) twice daily at improving pulmonary function. Differences between tiotropium–olodaterol and other LAMA/LABA FDCs were not observed for FEV1 or other efficacy markers. Therefore, tiotropium–olodaterol is a valuable option in the treatment of COPD patients who remain symptomatic under monotherapy. Keywords: COPD, bronchodilatation, dyspnea, exacerbation, exercise tolerance, LABA, LAMA, spirometryhttps://www.dovepress.com/efficacy-of-tiotropiumndasholodaterol-fixed-dose-combination-in-copd-peer-reviewed-article-COPDCOPDbronchodilatationdyspneaexacerbationexercise tolerance LABALAMAspirometry |
| spellingShingle | Derom E Brusselle GG Joos GF Efficacy of tiotropium–olodaterol fixed-dose combination in COPD International Journal of COPD COPD bronchodilatation dyspnea exacerbation exercise tolerance LABA LAMA spirometry |
| title | Efficacy of tiotropium–olodaterol fixed-dose combination in COPD |
| title_full | Efficacy of tiotropium–olodaterol fixed-dose combination in COPD |
| title_fullStr | Efficacy of tiotropium–olodaterol fixed-dose combination in COPD |
| title_full_unstemmed | Efficacy of tiotropium–olodaterol fixed-dose combination in COPD |
| title_short | Efficacy of tiotropium–olodaterol fixed-dose combination in COPD |
| title_sort | efficacy of tiotropium ndash olodaterol fixed dose combination in copd |
| topic | COPD bronchodilatation dyspnea exacerbation exercise tolerance LABA LAMA spirometry |
| url | https://www.dovepress.com/efficacy-of-tiotropiumndasholodaterol-fixed-dose-combination-in-copd-peer-reviewed-article-COPD |
| work_keys_str_mv | AT derome efficacyoftiotropiumndasholodaterolfixeddosecombinationincopd AT brussellegg efficacyoftiotropiumndasholodaterolfixeddosecombinationincopd AT joosgf efficacyoftiotropiumndasholodaterolfixeddosecombinationincopd |